Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease
A study for patients at risk for memory loss using study drug solanezumab
Sponsor: Eli Lilly and Company
Enrolling: Male and Female Patients
IRB Number: AAAM8752
U.S. Govt. ID: NCT02008357
Contact: Karen Bell: 212-305-9194 /
Additional Study Information: The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid. The study will also test 1) whether the anti-amyloid treatment can slow evidence of AD-related brain injury on imaging tests to look at brain structure and function and 2) the effect of solanezumab on cerebrospinal fluid (CSF) biomarkers and blood biomarkers. Solanezumab is an investigational drug which means that it has not been approved for routine clinical use or for the use described in this study by the U.S. Food and Drug Administration (FDA).
This study is closed
Karen Bell, MD
Do You Qualify?
Are you between the ages of 65-85? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Karen Bell